Opportunity Information: Apply for PA 10 079
Apply for PA 10 079
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Image Guided Cancer Interventions (SBIR R43/R44)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research.
- This funding opportunity was created on Jan 8, 2010 and posted on Jan 6, 2010.
- Applicants must submit their applications by Jan 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $100,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Image Guided Cancer Interventions (SBIR R43/R44) opportunity (Funding Opportunity Number PA-10-079) is a National Cancer Institute (NCI) funding announcement under the National Institutes of Health that is aimed specifically at small business concerns developing practical, clinically useful technology for image guided interventions (IGIs) in cancer. In plain terms, the program is looking for small companies that can build and prove out integrated systems that use medical imaging to help guide, monitor, and improve cancer treatments and procedures. The emphasis is not just on inventing a component or a single tool, but on developing systems that pull imaging, real-time monitoring, and therapy delivery together in a cohesive, usable workflow that can be evaluated in real clinical settings.
A central theme of the FOA is moving beyond early prototypes and into clinical validation. The goals include supporting development and optimization of fully integrated cancer imaging, monitoring, and therapy systems, and then validating those integrated IGI systems through clinical evaluations. Another practical goal is enabling the creation of multiple prototype systems when that is necessary to support multisite clinical evaluations, since meaningful clinical validation often requires testing at more than one hospital or clinical center. The FOA also explicitly encourages partnerships that help make that kind of translation possible, including collaborations among small businesses, large businesses, and academic clinical centers, as well as small business joint ventures. The intent behind these partnerships is to combine engineering and product development strengths with clinical expertise and real-world implementation environments so the resulting systems are more likely to be adoptable in routine care.
From a funding mechanism standpoint, this announcement uses the SBIR program under the R43/R44 grant mechanisms, meaning it supports Phase I, Phase II, and Fast Track applications. Phase I generally focuses on establishing feasibility and demonstrating that the core technical approach is workable, while Phase II supports more advanced development and validation steps. Fast Track allows applicants to apply for Phase I and Phase II in a combined submission to streamline the path from early feasibility to more extensive development. This SBIR FOA runs in parallel with an announcement of the same scientific intent for the STTR program (PA-10-080, using R41/R42 mechanisms), which is relevant for teams that prefer the STTR structure and its formal collaboration requirements.
The opportunity is listed as a discretionary grant, with activity areas spanning education and health, and it is associated with CFDA numbers 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research. There is no cost sharing or matching requirement stated. Eligibility is limited to small businesses, reflecting the SBIR program focus on stimulating innovation and commercialization potential within U.S. small companies.
In terms of award amounts and volume, the FOA notes that awards depend on the availability of funds and the number of high-quality applications received. In other words, there is not a guaranteed number of awards; funding decisions depend on scientific and technical merit, readiness for development and validation, alignment with program goals, and the proposed budget and timeline. The listing includes an award ceiling of 100,000, and the total amount awarded and the number of awards are described as variable based on application quality, duration, and costs.
Administratively, the FOA was posted January 6, 2010, with an original and current closing date of January 7, 2013, and an archive date of February 7, 2013, meaning it is no longer open for new applications under that specific posting. The sponsoring agency is NIH (via NCI), and the full announcement was made available through the NIH grants guide. Contact information provided is directed to the NIH Office of Extramural Research (OER) webmaster for issues accessing or linking to the announcement.
Frequently Asked Questions (FAQs): Image Guided Cancer Interventions (SBIR R43/R44) - PA-10-079
What is the Image Guided Cancer Interventions (SBIR R43/R44) funding opportunity?
It is a National Cancer Institute (NCI) funding announcement under the National Institutes of Health (NIH) focused on small business concerns developing practical, clinically useful technology for image guided interventions (IGIs) in cancer. The goal is to support systems that use medical imaging to guide, monitor, and improve cancer treatments and procedures.
What is the Funding Opportunity Number (FOA number) for this announcement?
The Funding Opportunity Number is PA-10-079.
Who is the sponsoring agency for this opportunity?
The sponsoring agency is the National Institutes of Health (NIH), specifically through the National Cancer Institute (NCI).
What type of applicants are eligible to apply?
Eligibility is limited to small businesses, consistent with the SBIR program focus on supporting innovation and commercialization potential within U.S. small companies.
What kinds of projects is this FOA looking to fund?
The FOA targets integrated image guided intervention (IGI) systems for cancer that combine medical imaging, real-time monitoring, and therapy delivery into a cohesive workflow that can be evaluated in real clinical settings.
Does the FOA emphasize single components or complete systems?
The emphasis is on developing integrated systems rather than inventing a single component or standalone tool. The program is looking for solutions that pull imaging, monitoring, and therapy delivery together in a clinically usable way.
What is a central theme of this funding announcement?
A central theme is moving beyond early prototypes into clinical validation. The FOA supports development and optimization of fully integrated systems and then validation through clinical evaluations.
Does the FOA support clinical evaluation and validation?
Yes. The FOA explicitly focuses on supporting clinical evaluations to validate integrated IGI systems.
Is multisite clinical evaluation mentioned or encouraged?
Yes. A practical goal described in the FOA is enabling the creation of multiple prototype systems when necessary to support multisite clinical evaluations, since meaningful clinical validation often requires testing at more than one hospital or clinical center.
Are partnerships or collaborations encouraged?
Yes. The FOA encourages partnerships that help translation into real-world clinical use, including collaborations among small businesses, large businesses, and academic clinical centers, as well as small business joint ventures.
Why does the FOA encourage partnerships?
The intent is to combine engineering and product development strengths with clinical expertise and real implementation environments so the resulting systems are more likely to be adoptable in routine care.
What funding mechanism is used for this announcement?
This announcement uses the SBIR program under the R43/R44 grant mechanisms.
Which project phases are supported under this SBIR FOA?
The FOA supports Phase I, Phase II, and Fast Track applications.
What is the general purpose of Phase I under this FOA?
Phase I generally focuses on establishing feasibility and demonstrating that the core technical approach is workable.
What is the general purpose of Phase II under this FOA?
Phase II supports more advanced development and validation steps.
What is Fast Track in the context of this FOA?
Fast Track allows applicants to apply for Phase I and Phase II in a combined submission to streamline the path from early feasibility to more extensive development.
Is there a related opportunity under STTR?
Yes. This SBIR FOA runs in parallel with an announcement of the same scientific intent for the STTR program: PA-10-080, using the R41/R42 mechanisms.
When might an applicant consider the STTR parallel announcement instead?
The parallel STTR announcement may be relevant for teams that prefer the STTR structure and its formal collaboration requirements.
What is the grant type listed for this opportunity?
The opportunity is listed as a discretionary grant.
What activity areas are associated with this funding opportunity?
The activity areas span education and health.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research) and 93.395 (Cancer Treatment Research).
Is cost sharing or matching required?
No cost sharing or matching requirement is stated in the information provided.
Is the number of awards fixed?
No. The FOA indicates that awards depend on the availability of funds and the number of high-quality applications received, so the number of awards is not guaranteed.
What factors influence whether an award is made?
Based on the information provided, funding decisions depend on scientific and technical merit, readiness for development and validation, alignment with program goals, and the proposed budget and timeline.
What is the award ceiling listed for this opportunity?
The listing includes an award ceiling of 100,000.
Are total award dollars and award counts specified?
They are described as variable based on application quality, duration, and costs, and are dependent on available funds.
When was this FOA posted?
The FOA was posted on January 6, 2010.
What was the closing date for applications?
The original and current closing date listed is January 7, 2013.
Is this funding opportunity still open?
No. It has an archive date of February 7, 2013, meaning it is no longer open for new applications under that specific posting.
Where was the full announcement made available?
The full announcement was made available through the NIH grants guide.
Who is listed as the contact for access or linking issues?
Contact information provided is directed to the NIH Office of Extramural Research (OER) webmaster for issues accessing or linking to the announcement.
Browse more opportunities from the same category: Education Health
Next opportunity: Image Guided Cancer Interventions (STTR R41/R42)
Previous opportunity: DHS ST Long Range Broad Agency Announcement
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 079
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 079) also looked into and applied for these:
| Funding Opportunity |
|---|
| Image Guided Cancer Interventions (STTR R41/R42) Apply for PA 10 080 Funding Number: PA 10 080 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Shared Instrumentation Grant Program (S10) Apply for PAR 10 082 Funding Number: PAR 10 082 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Systems Biology, HIV/AIDS, and Substance Abuse (R01) Apply for RFA DA 10 014 Funding Number: RFA DA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: $750,000 |
| Pre Application for the 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (X02) Apply for PAR 10 095 Funding Number: PAR 10 095 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| 2010 NIDA Translational Avant Garde Award for Medication Development for Diseases of Addiction (DP1) Apply for RFA DA 10 013 Funding Number: RFA DA 10 013 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medications Development for Substance Related Disorders (R01) Apply for RFA DA 10 018 Funding Number: RFA DA 10 018 Agency: National Institutes of Health Category: Education Health Funding Amount: $1,000,000 |
| Deep Sequencing and Analysis of Pharmacogenomic Regions Discovery and Analysis of Genetic Variants Contributing to Drug Abuse and Addiction (R01) Apply for RFA DA 10 019 Funding Number: RFA DA 10 019 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Institutional Clinical and Translational Science Award (U54) Apply for RFA RM 10 001 Funding Number: RFA RM 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R01) Apply for PAS 10 097 Funding Number: PAS 10 097 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Technology Based Adherence Interventions for Substance Abusing Populations with HIV (R34) Apply for PAS 10 098 Funding Number: PAS 10 098 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R01) Apply for RFA NR 10 001 Funding Number: RFA NR 10 001 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Chronic Co Morbid Conditions in HIV U.S. Adults on Highly Effective Anti Retroviral Therapy (R21) Apply for RFA NR 10 002 Funding Number: RFA NR 10 002 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows (Parent F31) Apply for PA 10 108 Funding Number: PA 10 108 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (Limited Competition U54) Apply for RFA CA 10 503 Funding Number: RFA CA 10 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R21) Apply for RFA NR 10 007 Funding Number: RFA NR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Palliative Care Research for Children Facing Life Limiting Conditions (R01) Apply for RFA NR 10 006 Funding Number: RFA NR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Common Pathogenetic Mechanisms of Lung Cancer and COPD (R01) Apply for RFA HL 11 002 Funding Number: RFA HL 11 002 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Clinical Trials in Drug Abuse (Collaborative R01) Apply for PAR 10 099 Funding Number: PAR 10 099 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Strategic Partnering to Evaluate Cancer Signatures SPECS II (U01) Apply for PAR 10 126 Funding Number: PAR 10 126 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Epigenetic Factors Associated with Symptoms and Complications of Chronic Disorders (Competitive Revision R01) Apply for RFA NR 10 005 Funding Number: RFA NR 10 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 079", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.